SK bioscience Co.,Ltd.

SK bioscience Co.,Ltd.

KKRX:302440
39,900.00
KRW
+600.00
(+1.53%)
-1,092.92EPS
2.80TMarket Cap
Feb 10Next Earn

Total Valuation

KRW

As of June 30, 2026, SK bioscience Co.,Ltd. carries a market capitalization of 2.80T, placing it among publicly traded companies globally. Its enterprise value stands at 2.78T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.80T
Enterprise Value2.78T

Important Dates

SK bioscience Co.,Ltd.'s next confirmed earnings release is scheduled for February 10, 2027.

Earnings Date2/10/2027

Share Statistics

As of June 30, 2026, SK bioscience Co.,Ltd. has 78.46M shares outstanding.

Shares Outstanding78.46M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 4.25, and the price-to-book ratio stands at 1.61.

PS Ratio4.25
PB Ratio1.61
P/TBV Ratio1.89
P/FCF Ratio-10.80
P/OCF Ratio626.63

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 4.21 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.78T versus a market cap of 2.80T, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.21

Financial Position

As of June 30, 2026, SK bioscience Co.,Ltd. maintains a current ratio of 3.60, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.08, indicating elevated leverage, while an interest coverage ratio of -2.61 demonstrates limited ability to service its debt obligations.

Current Ratio3.60
Quick Ratio2.49
Debt / Equity27.08
Debt / EBITDA-16.45
Interest Coverage-2.61

Financial Efficiency

KRW

Over the twelve months ended June 30, 2026, SK bioscience Co.,Ltd. posted a negative return on equity (ROE) of -4.79, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.90, reflecting losses generated across the asset base. The company generates approximately 598.25M in revenue per employee across its workforce of 1,102.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.73 indicates how many times SK bioscience Co.,Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-4.79
Return on Assets (ROA)-2.90
Revenue Per Employee598.25M
Employee Count1,102.00
Inventory Turnover2.73

Taxes

KRW

Over the twelve months ended June 30, 2026, SK bioscience Co.,Ltd. recorded an income tax benefit of -15.60B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -101.18B and -84.70B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-15.60B

Stock Price Statistics

KRW

As of the close on November 17, 2026, SK bioscience Co.,Ltd.'s stock has declined approximately 26.92% over the past 52 weeks. The 50-day moving average sits at 36,346.00, while the 200-day moving average is 40,086.50.

52-Week Price Change-26.92%
50-Day Moving Average36,346.00
200-Day Moving Average40,086.50

Income Statement

KRW

Over the twelve months ended June 30, 2026, SK bioscience Co.,Ltd. generated 659.27B in revenue and converted that into -84.70B in net income, yielding earnings per share of -1,092.92. EBITDA reached -33.04B, while operating income came in at -131.25B.

Revenue659.27B
Gross Profit94.27B
Operating Income-131.25B
Pretax Income-101.18B
Net Income-84.70B
EBITDA-33.04B
EBIT-131.25B
Earnings Per Share (EPS)-1,092.92

Balance Sheet

KRW

As of June 30, 2026, SK bioscience Co.,Ltd. holds 832.60B in cash and equivalents against 543.37B in total debt, resulting in a net debt position of 409.40B. Total book value stands at 1.75T, with working capital of 868.66B providing operational flexibility.

Cash & Cash Equivalents832.60B
Total Debt543.37B
Net Debt409.40B
Equity (Book Value)1.75T
Book Value Per Share22,256.52
Working Capital868.66B

Cash Flow

KRW

SK bioscience Co.,Ltd. produced 4.47B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -263.58B in capital expenditures, free cash flow totaled -259.12B - equivalent to -3,309.37 per share.

Operating Cash Flow4.47B
Capital Expenditures-263.58B
Free Cash Flow-259.12B
FCF Per Share-3,309.37

Margins

Over the twelve months ended June 30, 2026, SK bioscience Co.,Ltd. posted a gross margin of 14.30, reflecting its pricing power and cost economics. The operating margin of -19.91 and net profit margin of -12.85 provide insight into operational efficiency.

Gross Margin14.30
Operating Margin-19.91
Pretax Margin-15.35
Profit Margin-12.85
EBITDA Margin-5.01

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.26: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.03, meaning SK bioscience Co.,Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-3.03
FCF Yield-9.26

Scores

As of June 30, 2026, SK bioscience Co.,Ltd. has an Altman Z-Score of 2.39, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.39